--- title: "Fourier's bet on care robots turned a rehab firm into an RMB 8B unicorn" date: 2026-11-09 category: Capital & Markets site: NeuroAI canonical: https://neuroai.site/a/na-capital-fourier-series-e language: en --- # Fourier's bet on care robots turned a rehab firm into an RMB 8B unicorn > Fourier Intelligence closed a 2025 Series E near RMB 800M at a ~RMB 8B valuation — unicorn territory on hospital robots, not hype. A Shanghai company that started by helping stroke patients walk is now worth more than a billion dollars. Its path to that valuation ran through hospital wards, not conference stages. Fourier bet that rehabilitation robots and humanoids (人形机器人) could share the same muscles and motors — and investors bought the story. ## Key takeaways - Fourier Intelligence closed a **Series E in early 2025 of about RMB 800 million (≈ US$113M / HK$880M)** at a valuation later disclosed near **RMB 8 billion (≈ US$1.13B / HK$8.8B)**. - A later 2025 strategic investment from Runyang Technology of about **RMB 300 million (≈ US$42M / HK$330M)** kept the valuation around RMB 8 billion. - Baidu Baike calls it the first unicorn in China's embodied intelligence (具身智能) field — a claim worth flagging, not just repeating. - Unlike pure humanoid (人形机器人) startups, Fourier ships revenue-generating medical hardware today, which is the cushion behind the bet. ## The round, in numbers Fourier Intelligence (傅利叶智能), founded in Shanghai in 2015 by Gu Jie (顾捷), began in rehabilitation robotics — exoskeletons and therapy devices — before pivoting into general-purpose humanoids. The verified financing picture: - **Series E, early 2025:** roughly **RMB 800 million (≈ US$113M / HK$880M)**, led by state-linked Guoxin Investment, alongside Pudong Venture Capital, Zhangjiang Venture Capital, Prosperity7 (Saudi Aramco's venture arm) and Junshan Capital. - **Valuation:** about **RMB 8 billion (≈ US$1.13B / HK$8.8B)** post-money — above the US$1B line that defines a unicorn. - **Strategic round, 2025:** Runyang Technology (润阳科技, 300920.SZ) committed about **RMB 300 million (≈ US$42M / HK$330M)** at a pre-money valuation near RMB 8 billion, per Baidu Baike and Phoenix Weekly reporting. - **Total raised to date:** tracked by industry databases at roughly US$200M–290M across earlier rounds, including a 2022 Series D of about RMB 400 million led by SoftBank's Vision Fund. The company's rehabilitation exoskeleton holds a leading domestic market share, with overseas revenue near 20% and deployments across 40-plus countries. ## Why care robots are the anchor Most humanoid (人形机器人) startups burn cash on a dream. Fourier's difference is a paying customer base that already exists: hospitals. Its lower-limb exoskeletons and therapy robots generate real revenue and give the firm a "safety cushion," as one exchange-linked analyst quoted by Phoenix Weekly put it. That cash flow funds the riskier humanoid (人形机器人) program without starving the core business. The humanoid (人形机器人) line — the GR series — is the growth story. The GR-1, unveiled in 2023, was among the first Chinese general-purpose humanoids to reach 量产 (mass production). The GR-3, shown in 2025, is pitched as a care and companion bot with 55 degrees of freedom and multimodal sensing. ## The Meta wrinkle In 2025, Fourier drew attention for a quiet partnership with Meta. Reporting by The Information, cited by Chinese outlets, said Meta used Fourier as the hardware builder for a humanoid prototype code-named "Max," with Meta's team embedded in Fourier's Shanghai factory. The framing matters. Analysts described it as an ODM-style prototype build: Meta defined the brain and the scenario; Fourier built the body. That is a vote of confidence in Chinese robotics manufacturing — but also a warning that the higher-margin "AI brain" value may sit with the US partner, while the "engineering body" earns thinner margins. ## The honest risks Two cautions are worth stating plainly. First, **the unicorn label is a claim, not a verdict.** Baidu Baike states Fourier is the first embodied intelligence (具身智能) unicorn in China; that is a reference-site assertion, not an audited ranking. The RMB 8 billion valuation, however, is well sourced. Second, **humanoid (人形机器人) revenue is still small.** Gu Jie has said GR-series 2025 deliveries targeted only a few hundred units, with much of the near-term humanoid income coming from R&D, education and data collection rather than factory or elder-care work. At a 2026 Shanghai CPPCC session he noted that core components still account for more than 60% of a unit's cost — the kind of detail that keeps margins thin. ## What readers can do now - **If you build or buy robots:** benchmark Fourier's rehab hardware on a real clinical task before assuming a flashier humanoid (人形机器人) startup is more capable. - **If you follow listings:** Fourier is reported to be preparing a STAR Market filing; a prospectus, not a rumor, is the proof. - **If you invest in China AI:** separate the paying rehab business from the priced-for-the-future humanoid (人形机器人) bet — the first funds the second. ## Honest limitations Core facts — 2015 Shanghai founding by Gu Jie; Series E early 2025 ~RMB 800M (≈ US$113M / HK$880M) led by Prosperity7/Guoxin/Pudong VC at ~RMB 8B (≈ US$1.13B / HK$8.8B) valuation; 2025 Runyang New Material strategic ~RMB 300M (≈ US$42M / HK$330M) at ~RMB 8B pre-money; SoftBank Vision Fund-led 2022 Series D ~RMB 400M; leading domestic rehab exoskeleton share, ~20% overseas revenue, 40+ countries; GR-1 (2023) and GR-3 (2025, 55 DoF) humanoids — come from Baidu Baike, Phoenix Weekly / Tencent News (Nov 2026), and Sterling Charts / FOBI company profiles. The "first embodied intelligence unicorn" phrasing is Baidu Baike's claim, attributed as such. The Meta "Max" prototype and ODM framing come from The Information via Chinese media; treat the commercial structure as reported, not confirmed by either company. Gu Jie’s few-hundred-unit 2025 GR delivery target and >60% component-cost remark are from Phoenix Weekly and his 2026 Shanghai CPPCC comments. Currency uses fixed rates RMB 7.1 = US$1, RMB 1 = HK$1.1; conversions approximate. Round size and valuation are reported/disclosed figures, not an official audited statement beyond company and investor disclosures. Not investment advice. Current to 9 November 2026. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-capital-fourier-series-e Free to quote with attribution and a link to the original.